ACTIVE

Hyloris

Export PDF
Financial year 2025 · closed on 31/12/2025
Net result
-100,5 k €
-541.7% YoY
Revenue
384,9 k €
Equity
706,2 k €
+141.7% YoY

What does Hyloris do?

Hyloris is a Public limited company incorporated in 2017. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Liège.

Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0669.738.676
Incorporation
18/01/2017
Legal form
Public limited company
Registered office
Boulevard de Patience et Beaujonc 3 box 1
4000 Liège · WallonieSee on map
Contributed capital
806 742,00 €
Latest accounts
31/12/2025
Activities (NACE)
46460Wholesale of pharmaceutical goods· main46460Wholesale of pharmaceutical goods21100Manufacture of basic pharmaceutical products21100Manufacture of basic pharmaceutical products
Signals
Solid equityGood liquidityPositive EBITDA
View the BCE/KBO Public Search record →
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 8 financial years

20252024202320222021202020192018
Income statement
Revenue384,9 k €–53,3 k €–––––
EBITDA33,3 k €170,1 k €33 k €-5,7 k €14,1 k €-476,8 k €-3 k €-499,7 k €
Operating result44,6 k €168,6 k €-97,1 k €-77,1 k €-139,4 k €-649,8 k €-43,9 k €-499,7 k €
Net result-100,5 k €22,8 k €-146,6 k €-148,5 k €-235,8 k €-659 k €-69,4 k €-518,7 k €
Balance sheet
Equity706,2 k €-1,7 M €-1,7 M €-1,6 M €-1,4 M €-1,2 M €-526,1 k €-456,7 k €
Total assets1,6 M €996,6 k €1 M €722,4 k €3,9 M €12,7 M €279,6 k €43,3 k €
Cash298,7 k €580,5 k €699,2 k €690,4 k €3,9 M €12,5 M €7,1 k €30,3 k €
Debts872,2 k €2,7 M €2,5 M €2,1 M €5,1 M €13,8 M €767,5 k €485,1 k €
Estimate

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€
See the valuation
Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 8 ended

Active mandates

Jacobsen Management

Director · since 20 avril 2020 · until 09 juin 2026 · 0736.534.955

Represented by Thomas Jacobsen

Active
SVR Management

Managing director · since 20 avril 2020 · until 09 juin 2026 · 0552.806.859

Represented by Stijn Van Rompay

Active

Ended mandates

Jacobsen Management

Director · since 20 avril 2020 · until 20 avril 2026 · 0736.534.955

Represented by Thomas Jacobsen

Ended
SVR Management

Director · since 20 avril 2020 · until 20 avril 2026 · 0552.806.859

Represented by Stijn Van Rompay

Ended
SVR Management

Managing director · since 20 avril 2020 · until 20 avril 2026 · 0552.806.859

Represented by Stijn Van Rompay

Ended
GRNR Invest

Director · since 18 juin 2017 · until 20 avril 2020 · 0817.694.459

Represented by Thomas Jacobsen

Ended
At this address

Other companies at this address

CompanyCBE no.
Abscint● Active
0749.828.410
AMPACIMON● Active
0827.990.317
Amyl Therapeutics● Active
0758.775.372
BECARV● Bankrupt
0840.777.885
BE.SPINE● Active
1013.110.857
CEFALY Technology● Active
0870.578.661
DERMAX● Active
0667.730.677
DIANOSIC● Active
1034.558.646
DW Cefaly Holding● Active
0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active
1023.778.481
EXO Biologics● Active
0732.982.379
ExoXpert● Active
1003.807.666
Hirundo Biosciences● Active
0681.855.065
HolyFox Invest● Active
1010.693.181
Hyloris Developments● Active
0542.737.368
Hyloris Pharmaceuticals● Active
0674.494.151
Hyloris Therapeutics● Active
1025.029.385
LEGIAPARK● Active
0728.589.170
MAN & SCIENCE● Active
0837.403.770
ONCORADIOMICS● Active
0662.719.440
Annual accounts

Full financial information

202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date07/07/202604/07/202515/11/202411/07/202312/07/202206/07/2021
General meeting30/06/202610/06/202514/11/202413/06/202314/06/202208/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

9 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202530/06/202607/07/2026FrenchPDF
Abridged model31/12/202410/06/202504/07/2025FrenchPDF
Abridged model31/12/202314/11/202415/11/2024FrenchPDF
Abridged model31/12/202213/06/202311/07/2023FrenchPDF
Abridged model31/12/202114/06/202212/07/2022FrenchPDF
Abridged model31/12/202008/06/202106/07/2021FrenchPDF
Abridged model31/12/201908/06/202030/07/2020FrenchPDF
Micro modelCorrection31/12/201808/06/202030/05/2022FrenchPDF
Micro model31/12/201812/08/201926/08/2019FrenchPDF
Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 8 ended

Active mandates

Jacobsen Management

Director · since 20 avril 2020 · until 09 juin 2026 · 0736.534.955

Represented by Thomas Jacobsen

Active
SVR Management

Managing director · since 20 avril 2020 · until 09 juin 2026 · 0552.806.859

Represented by Stijn Van Rompay

Active

Ended mandates

Jacobsen Management

Director · since 20 avril 2020 · until 20 avril 2026 · 0736.534.955

Represented by Thomas Jacobsen

Ended
SVR Management

Director · since 20 avril 2020 · until 20 avril 2026 · 0552.806.859

Represented by Stijn Van Rompay

Ended
SVR Management

Managing director · since 20 avril 2020 · until 20 avril 2026 · 0552.806.859

Represented by Stijn Van Rompay

Ended
GRNR Invest

Director · since 18 juin 2017 · until 20 avril 2020 · 0817.694.459

Represented by Thomas Jacobsen

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Mandates26/09/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Capital / shares17/09/2025
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - CAPITAL, ACTIONS
    PDF
  • Mandates05/03/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates25/10/2024
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - DENOMINATION
    PDF
  • Mandates08/08/2023
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - DENOMINATION
    PDF
  • Mandates19/05/2023
    DEMISSIONS, NOMINATIONS
    PDF
  • Registered office20/10/2022
    SIEGE SOCIAL - DIVERS
    PDF
  • Registered office14/09/2022
    SIEGE SOCIAL
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-100,5 k €↓
  2. 2024
    Annual accounts 202422,8 k €↑
  3. 2024
    Name changeHyloris
  4. 2023
    Annual accounts 2023-146,6 k €↑
  5. 2023
    Name changeHYLORIS SUPPLY
  6. 2022
    Annual accounts 2022-148,5 k €↑
  7. 2021
    Annual accounts 2021-235,8 k €↑
  8. 2020
    Annual accounts 2020-659 k €↓
  9. 2019
    Annual accounts 2019-69,4 k €↑
  10. 2018
    Annual accounts 2018-518,7 k €
  11. 2018
    Name changeRTU PHARMA
  12. 18/01/2017
    IncorporationPublic limited company